This page contains a Flash digital edition of a book.
Why only treat half the problem?


For the half of men with LUTS who experience mixed bladder and prostate symptoms,1 is likely to treat only half the issue.2


Vesomni™ (solifenacin 6mg/tamsulosin 0.4mg) Prescribing Information Presentation: Vesomni™ 6mg/0.4mg modifi ed release tablets containing a layer of 6mg solifenacin


succinate and a layer of 0.4mg tamsulosin hydrochloride. Indication: Treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy. Dosage: Adult males (including older people): Recommended dose: One tablet (6mg/0.4mg) once daily taken orally with or without food. Children and adolescents: No relevant indication for use in children and adolescents. Contraindications: Patients hypersensitive to the active substance or any of the excipients, or undergoing haemodialysis, or with severe hepatic impairment, or with severe renal or moderate hepatic impairment and also treated with a strong CYP3A4 inhibitor. Severe gastrointestinal conditions (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma and patients at risk for these conditions. Patients with a history of orthostatic hypotension. Warnings and Precautions: Use with caution in patients with: severe renal impairment, risk of urinary retention, gastrointestinal obstructive disorders, risk of decreased gastrointestinal motility, hiatus hernia/gastroesophageal refl ux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis, autonomic neuropathy. Other conditions which can cause symptoms similar to BPH should be investigated and excluded. Other causes of frequent urination (heart failure or renal disease) should be assessed. Treat urinary tract infections with appropriate antibacterial therapy if present. QT prolongation and Torsade de Pointes have been observed in patients with risk factors such as pre-existing long QT syndrome and hypokalaemia, treated with solifenacin succinate. Angioedema with airway obstruction have been reported in some patients on solifenacin succinate and tamsulosin. Anaphylactic reaction has been reported in some patients treated with solifenacin succinate. Vesomni™


should be discontinued if angioedema occurs, or in patients who develop anaphylactic reactions and appropriate therapy


should be cautioned to sit or lie down at the fi rst signs of orthostatic hypotension (dizziness, weakness) until the symptoms have disappeared. Initiation of Vesomni™


and/or measures should be taken. A reduction in blood pressure can occur during treatment with tamsulosin, as a result of which, rarely, syncope can occur. Patients starting treatment with Vesomni™


is not recommended in


patients for whom cataract or glaucoma surgery is scheduled. Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract and glaucoma surgery and may increase the risk of eye complications during and after the operation in some patients on or previously treated with tamsulosin. During the pre-operative assessment, cataract surgeons and ophthalmic teams should consider whether patients scheduled for cataract or glaucoma surgery are being or have been treated with tamsulosin in order to ensure appropriate measures are in place to manage the IFIS during surgery. Use with caution in combination with moderate and strong CYP3A4 inhibitors and it should not be used with strong CYP3A4 inhibitors in patients who are of the CYP2D6 poor metaboliser phenotype or who are using strong CYP2D6 inhibitors. Interactions: Concomitant medication with any medicinal products with anticholinergic properties may result in more pronounced therapeutic effects and undesirable effects. Allow one week after stopping Vesomni™


before commencing any anticholinergic therapy. Concomitant administration of Vesomni™ with moderate and strong


inhibitors of CYP3A4 may lead to increased exposure to both tamsulosin and solifenacin. Solifenacin can reduce the effect of stimulators of gastrointestinal tract motility. Co-administration with other alpha1


-adrenoceptor antagonists could lead to hypotensive effects. Diclofenac and warfarin


Nausea and abdominal pain were also commonly reported events for solifenacin. In post-marketing surveillance for solifenacin, Torsade de Pointes, electrocardiogram QT prolonged,


may increase the elimination rate of tamsulosin. Adverse Effects: Dry mouth, constipation, dyspepsia, dizziness, blurred vision, fatigue, ejaculation disorders, pruritus and urinary retention for Vesomni.™


References: 1. Sexton CC et al. BJU Int 2009; 103(Suppl 3): 12–23. 2. Lee JY et al. BJU Int 2004; 94(6): 817–820. 3. NICE clinical guidelines 2010. The management of lower urinary tract symptoms in men, CG97.


4. VESOMNI Summary of Product Characteristics, October 2013. Date of preparation: June 2015 Job Code: VSO15017UKa


atrial fi brillation, tachycardia have been observed. During post-marketing surveillance of tamsulosin, IFIS has occurred in some patients during cataract surgery. Atrial fi brillation, arrhythmia, tachycardia and dyspnoea have also been reported in association with tamsulosin use from post-marketing experience. Prescribers should consult the Summary of Product Characteristics in relation to other side effects. Pack and prices: Vesomni™


6mg/0.4mg pack of 30 tablets £27.62 Legal Category: POM. Product Licence Number: Vesomni™ 6mg/0.4mg PL 00166/0404. Date of Preparation:


December 2013. Further information available from: Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS, UK. Vesomni™


is a Registered Trademark. For full prescribing information


please refer to the Summary of Product Characteristics. For Medical Information phone 0800 783 5018.


Adverse events should be reported. Reporting forms


and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Astellas Pharma Ltd. Please contact 0800 783 5018


an α-blocker So if your patients don’t fi nd relief from an α-blocker alone, choose VESOMNI, the only licensed treatment in one pill to address both symptom types at once.3,4


tamsulosin OCAS 0.4mg/solifenacin 6mg Two problems, one solution


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108